Dato-DXd Antibody-Drug Conjugate for Triple-Negative and Hormone Receptor-Positive MBC - Metastatic Breast Cancer Trial Talk

Research News

Antibody-drug conjugates (ADCs) consist of an antibody attached to a chemotherapy drug that delivers chemotherapy only where it is needed, limiting unwanted side effects. ADCs work by combining the ability of antibodies to target cancer cells with the ability of chemotherapy drugs to kill cancer cells.  

Three ADCs are approved for MBC: trastuzumab emtansine (Kadcyla®, T-DM1) for HER2+ MBC, trastuzumab deruxtecan (Enhertu®, T-DXd) for HER2+ and HER2-low MBC, and sacituzumab govitecan (Trodelvy®, SG) for hormone receptor-positive MBC and triple-negative MBC. 

This month, we are highlighting a new experimental ADC called datopotamab deruxtecan (Dato-DXd), which, like Trodelvy®, targets a molecule called TROP2. TROP2 is found in over 75% of breast cancers. Dato-DXd is not yet FDA approved and is being tested in clinical trials in people with hormone receptor-positive, HER2-negative MBC and triple-negative MBC. 

Read below for general information about how ADCs work and for research news about Dato-DXd. 

About ADCs 

Dato-DXd for Triple-Negative MBC 

Dato-DXd for Hormone Receptor-Positive MBC 

Clinical Trials 


Last Modified on February 29, 2024



for past articles or specific information.